All In Biotech

Drug Trial Radar · NCT01482962

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Jul 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 271 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

271

Actual

Start

Jun 11, 2012

Primary completion

Jun 30, 2015

Study completion Dec 18, 2017

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Dec 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL). Note: romidepsin was not used as a single-agent comparator outside the United States of America (USA) as supply was not available.

Conditions

  • Relapsed Peripheral T-Cell Lymphoma
  • Refractory Peripheral T-Cell Lymphoma

Interventions

  • AlisertibDrug

    Alisertib enteric coated tablets

  • PralatrexateDrug

    Pralatrexate IV infusion

  • GemcitabineDrug

    Gemcitabine IV infusion

  • RomidepsinDrug

    Romidepsin IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) Based on Independent Review Committee (IRC) AssessmentTime frame: Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
  2. Progression-Free Survival (PFS) Based on IRC AssessmentTime frame: Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years

Locations

151 sites in 31 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    La Jolla, California

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Rochester, Minnesota

  • Site not named

    Jefferson City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Hackensack, New Jersey

  • Site not named

    Buffalo, New York

  • Site not named

    New York, New York

  • Site not named

    Syracuse, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Columbus, Ohio

  • Site not named

    Toledo, Ohio

  • Site not named

    Charleston, South Carolina

  • Site not named

    Houston, Texas

  • Site not named

    Burlington, Vermont

  • Site not named

    Seattle, Washington

  • Site not named

    Morgantown, West Virginia

  • Site not named

    Adelaide, Australia

  • Site not named

    Concord, Australia

  • Site not named

    Gosford, Australia

  • Site not named

    Hobart, Australia

  • Site not named

    St Leonards, Australia

  • Site not named

    Graz, Austria

  • Site not named

    Innsbruck, Austria

  • Site not named

    Salzburg, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Minsk Didtrict, Belarus

  • Site not named

    Vitebsk, Belarus

  • Site not named

    Bruges, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Kortrijk, Belgium

  • Site not named

    Turnhout, Belgium

Showing 40 of 151 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.